MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC), a European-based pharmaceutical company specialising in the production and development of plant-inspired medicines, has appointed experienced life-sciences executive Layton Mills as a non-executive director of the company.
The company expects to benefit from the experience of Mills, who has worked in the biotechnology and life sciences industries for more than 15 years.
Appropriate experience
During this time, he has developed experience across human and animal health in pharmaceutical and consumer healthcare.
MGC Pharma is confident this appointment will help meet its goal of finding or producing treatments for unmet medical conditions.
The company’s core business strategy is to develop and supply high-quality plant-inspired medicines for the growing demand in the medical markets in Europe, North America and Australasia.
Mills’ appointment is expected to strengthen the leadership team with the founders and executives of the company being key figures in the global pharmaceuticals industry.
Biotechnology roles
The new MGC Pharma director is the founder of CannPal Animal Therapeutics Pty Ltd, an animal health company developing cannabinoid-based veterinary medicines for FDA-CVM registration,
He led this company through an Initial Public Offering on the Australian Stock Exchange, followed by an acquisition by AusCann Group Holdings in 2021 where he served as CEO.
Mills is also the founder and managing director of Subgenix Lifesciences, an early-stage biotechnology company using conventional drug development strategies to unlock the broader therapeutic potential of psychedelic compounds for rare and underserved health needs.
He has extensive international business experience having been involved in corporate business activities across Europe, Asia and North America, including government-led trade incentives with the Canberra Business Chamber.
About MGC Pharma
MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development.
The company has partnered with renowned institutions and academia to optimise the development of targeted plant-inspired medicines, to be produced in its' EU-GMP Certified manufacturing facilities.
MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.